Seeing Is Believing
Currently out of the existing stock ratings of Hartaj Singh, 149 are a BUY (93.13%), 2 are a SELL (1.25%), 9 are a HOLD (5.63%).
Analyst Hartaj Singh, currently employed at OPPENHEIMER, carries an average stock price target met ratio of 38.25% that have a potential upside of 29.16% achieved within 212 days.
Hartaj Singh’s has documented 314 price targets and ratings displayed on 26 stocks. The coverage is on the Healthcare sector.
Most recent stock forecast was given on REGN, Regeneron Pharmaceuticals at 10-Jan-2025.
Analyst best performing recommendations are on ONCT (ONCTERNAL THERAPEUTICS).
The best stock recommendation documented was for MRNA (MODERNA) at 4/15/2020. The price target of $43 was fulfilled within 2 days with a profit of $5.75 (15.44%) receiving and performance score of 77.18.
Average potential price target upside
Analyst name
Rating
Current price target
Potential Upside
Previous price target
Date
Price targets met ratio
Average potential upside
Average Time (Days) For PT To Be Met
Performance score
Buy
$205
$22.5 (12.33%)
3 years 10 months 22 days ago
(05-May-2021)
3/5 (60%)
$35.09 (20.65%)
938
Hold
$173
$-9.5 (-5.21%)
$156
3 years 10 months 24 days ago
(03-May-2021)
14/24 (58.33%)
$2.73 (1.60%)
682
Hold
$190
3 years 11 months 1 days ago
(26-Apr-2021)
9/11 (81.82%)
$34.41 (22.12%)
350
Hold
$166
$-16.5 (-9.04%)
$175
4 years 1 months 23 days ago
(04-Feb-2021)
23/23 (100%)
$10.41 (6.69%)
828
Buy
$155
4 years 2 months 20 days ago
(07-Jan-2021)
7/7 (100%)
$36.79 (31.12%)
395
Which stock is Hartaj Singh is most bullish on?
Which stock is Hartaj Singh is most reserved on?
What Year was the first public recommendation made by Hartaj Singh?